Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Rhea-AI Summary
Liminatus Pharma (Nasdaq: LIMN) will implement a 1-for-50 reverse stock split of its common stock, effective at the close of trading on August 20, 2026, following prior stockholder approval at the 2026 Annual Meeting.
According to Liminatus, trading on a split-adjusted basis on the Nasdaq Capital Market will begin at market open on August 21, 2026 under the existing symbol LIMN, with a new CUSIP of 53271X 207. Every 50 issued and outstanding shares will be automatically combined into one share, with fractional shares rounded up to the nearest whole share and no cash in lieu. The reverse split will not change the par value or the number of authorized common or preferred shares, and stockholders’ proportional ownership and voting power will remain substantially unchanged, aside from nominal adjustments from fractional-share rounding.
Positive
- Reverse stock split ratio set at 1-for-50 with effective date
- Outstanding shares reduced from 67,160,362 to approximately 1,343,208 if applied July 2, 2026
- No cash paid for fractional shares; amounts are rounded up
- Equity awards, warrants and convertibles adjusted proportionately
- Shares continue trading on Nasdaq under existing symbol LIMN
Negative
- Reverse stock split consolidates every 50 existing shares into one
- No cash consideration provided for eliminated fractional shares
- Authorized share counts unchanged, allowing potential for future issuance at post-split levels
News Explained
The approved split would reduce reported shares to approximately 1.34 million without changing existing holders’ proportional ownership.
The board has adopted resolutions approving the stockholder-approved 1-for-50 reverse split, scheduled to take effect at the close of trading on
A reverse stock split combines shares and proportionally raises the per-share price, while the split itself does not change company value; Liminatus says proportional ownership and voting power remain unchanged except for nominal fractional-share adjustments.
The company also says equity awards, warrants, and other convertible securities will receive proportional adjustments to their underlying shares and exercise or conversion prices.
Market reaction after 1-for-50 reverse stock split: LIMN -11.38%
Following this news, LIMN has declined 11.38%, reflecting a significant negative market reaction. Argus tracked a trough of -8.9% from its starting point during tracking. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.12.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 13 | Nasdaq compliance extension | Positive | +32.5% | Nasdaq Capital Market transfer and extension to regain minimum bid-price compliance |
| Jun 30 | Merger amendment | Positive | +4.0% | InnocsAI merger terms were restructured to facilitate closing before stockholder approval |
| Jun 03 | Warrant exercise transaction | Negative | -22.2% | Investors exercised existing warrants while receiving new warrants at a lower exercise price |
| May 21 | Nasdaq delisting notification | Negative | -31.1% | Nasdaq cited failures to satisfy market-value requirements for continued listing |
| May 21 | Proposed merger | Positive | +31.0% | InnocsAI acquisition added oncology cell-therapy programs and contingent value rights |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
LIMN's five recent news events all aligned with their subsequent 24-hour price reactions, including both positive and negative catalysts.
Key Terms
reverse stock split financial
cusip number technical
par value financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock split of its common stock, par value
At the effective time of the Reverse Stock Split, every 50 issued and outstanding shares of Common Stock will be automatically combined into one share of Common Stock. No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares will have such shares rounded up to the nearest whole share, and no cash or other consideration will be paid in connection with any fractional shares that would otherwise have resulted from the Reverse Stock Split.
The Reverse Stock Split has no effect on the par value of the Common Stock or authorized shares of Common Stock or preferred stock. Each stockholder’s proportionate ownership interest in the Company and proportional voting power will remain unchanged (except for nominal adjustments resulting from the treatment of fractional shares). If the Reverse Stock Split were implemented as of July 2, 2026, the total number of outstanding shares would be reduced proportionately from 67,160,362 to approximately 1,343,208. Proportionate adjustments will be made to the number of shares underlying the Company’s outstanding equity awards and to the exercise or conversion prices of such instruments. Similar adjustments will be made to outstanding warrants and other convertible securities.
Stockholders holding their shares in book-entry form or through a bank, broker or other nominee will have their holdings automatically adjusted to reflect the Reverse Stock Split. Stockholders holding paper certificates may (but are not required to) send the certificates to the Company’s transfer agent and registrar, Continental Stock Transfer & Trust Company, who will issue a new stock certificate reflecting the Reverse Stock Split to each requesting stockholder.
About Liminatus Pharma, Inc.
Liminatus is a biotechnology company developing novel immune-modulating cancer therapies. The Company’s pipeline includes antibody-based immunotherapies and cellular therapies for the treatment of solid tumors and hematologic malignancies. Its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody, and the Company is also advancing additional oncology assets, including dual-target CAR-T therapies, solid tumor CAR-T therapy, and a CS1 Antibody platform acquired through its recently acquisition of InnocsAI.
Forward-Looking Statements
The information in this press release includes “forward-looking statements” within the meaning of the federal securities laws. All statements that are not statements of historical fact are forward-looking statements. Forward-looking statements may be identified by the use of words such as “may,” “could,” “would,” “should,” “predict,” “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” or other similar expressions that predict or indicate future events or that are not statements of historical matter. These statements are based on assumptions and on the current expectations of the Company’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of Liminatus. These forward-looking statements are subject to a number of risks and uncertainties, including: (i) changes in business, market, financial, political and legal conditions; (ii) Company’s continued ability to implement business plans; (iii) the risk of downturns, new entrants and a changing regulatory landscape in a highly competitive industry in which the Company operates; and (iv) those risks and uncertainties discussed in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements address matters that are, to varying degrees, uncertain and subject to risks, uncertainties, and assumptions, many of which that are beyond the Company’s control, that could cause actual results to differ materially from those expressed in any forward-looking statements. Forward-looking statements are not guarantees of future results. The forward-looking statements contained in this press release speak only as of the date of this press release and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.
Contacts:
Chris Kim, CEO
info@liminatuspharma.com
(213) 273-5453
